keyword
MENU ▼
Read by QxMD icon Read
search

Travoprost

keyword
https://www.readbyqxmd.com/read/28239491/efficacy-and-tolerability-of-travoprost-0-004-timolol-0-5-fixed-dose-combination-for-the-treatment-of-primary-open-angle-glaucoma-or-ocular-hypertension-inadequately-controlled-with-beta-blocker-monotherapy
#1
Simon Fabian Lerner, Ki Ho Park, Douglas A Hubatsch, Valeriy Erichev, Jose A Paczka, Timothy V Roberts
Objective. To evaluate the efficacy and tolerability of travoprost 0.004%/timolol 0.5% fixed-dose combination (TTFC) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) inadequately controlled on beta-blocker monotherapy. Methods. In this phase IV, open-label study, 156 patients on beta-blocker monotherapy with mean intraocular pressure (IOP) between 18 and 32 mmHg were randomized (no washout period) to receive TTFC for 8 weeks (TTFC group) or to continue beta-blocker monotherapy for 4 weeks followed by TTFC for the remaining 4 weeks (beta-blocker group)...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/28178150/the-effects-of-selective-laser-trabeculoplasty-and-travoprost-on-circadian-intraocular-pressure-fluctuations-a-randomized-clinical-trial
#2
RANDOMIZED CONTROLLED TRIAL
Weerawat Kiddee, Supreeya Atthavuttisilp
BACKGROUND: To compare the effect of selective laser trabeculoplasty (SLT) and travoprost on 24-hour IOP fluctuations in primary open-angle glaucoma (POAG) and normal-tension glaucoma (NTG). METHODS: Sixty eyes were included. Sixteen and 14 eyes of POAG patients were randomized to receive 360° SLT or 0.004% travoprost, respectively. Fourteen and 16 eyes of NTG patients were randomized to receive either SLT or travoprost, respectively. The 24-hour IOP data were collected before treatment and 6 to 8 weeks after treatment...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28146132/a-novel-convergent-synthesis-of-the-potent-antiglaucoma-agent-tafluprost
#3
Małgorzata Krupa, Michał Chodyński, Anna Ostaszewska, Piotr Cmoch, Iwona Dams
Tafluprost (AFP-168, 5) is a unique 15-deoxy-15,15-difluoro-16-phenoxy prostaglandin F2α (PGF2α) analog used as an efficacious ocular hypotensive agent in the treatment of glaucoma and ocular hypertension, as monotherapy, or as adjunctive therapy to β-blockers. A novel convergent synthesis of 5 was developed employing Julia-Lythgoe olefination of the structurally advanced prostaglandin phenylsulfone 16, also successfully applied for manufacturing of pharmaceutical grade latanoprost (2), travoprost (3) and bimatoprost (4), with an aldehyde ω-chain synthon 17...
January 31, 2017: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/28053501/fixed-combination-of-travoprost-and-timolol-maleate-reduces-intraocular-pressure-in-japanese-patients-with-primary-open-angle-glaucoma-or-ocular-hypertension-analysis-by-prostaglandin-analogue
#4
Tadashi Nakano, Shiro Mizoue, Nobuo Fuse, Aiko Iwase, Shun Matsumoto, Keiji Yoshikawa
BACKGROUND: We have shown a decrease in mean intraocular pressure (IOP) by switching to travoprost/timolol fixed combination (TTFC) in subjects receiving prostaglandin analogue (PGA) monotherapy and requiring additional medication in a previous report. For analyzing factors affecting IOP reduction, baseline IOP and preceding PGA were selected as statistically and clinically significant factors. In this report, we examine IOP-lowering effect and adverse drug reactions by preceding PGA...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/27993589/adherence-to-fixed-combination-versus-unfixed-travoprost-0-004-timolol-0-5-for-glaucoma-or-ocular-hypertension-a-randomized-trial
#5
Howard S Barnebey, Alan L Robin
PURPOSE: To assess adherence to treatment with fixed-combination travoprost 0.004%/timolol 0.5% (TTFC) compared with separate containers of travoprost 0.004% and timolol 0.5% (TRAV+TIM; unfixed) using electronic dosing aids DESIGN: Randomized, controlled, observer-masked clinical trial METHODS: Setting: Two US clinical sites Patient Population: Eligible patients were adults diagnosed with open-angle glaucoma or ocular hypertension. Patients (n=81) were sequentially randomized 1:1 to receive TTFC or TRAV+TIM for 12 months...
December 16, 2016: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/27822015/impossibility-to-eliminate-observer-effect-in-the-assessment-of-adherence-in-clinical-trials
#6
Jonathan S Myers, Scott J Fudemberg, Robert E Fintelmann, Lisa A Hark, Nitasha Khanna, Benjamin E Leiby, Michael Waisbourd
PURPOSE: To utilize the Travoprost Dosing Aid (DA) in the assessment of patient medication adherence, while also determining whether or not altering the functionality of the DA in three randomized subject groups can reduce observer effect. METHODS: Forty-five subjects were randomized into three groups: two with monitored DAs and one without monitoring. One group of subjects was given a DA that both monitored drop usage and had visual and audible alarms, while the other monitored group included subjects given a DA that had no alarms but continued to monitor drop usage...
2016: Patient Preference and Adherence
https://www.readbyqxmd.com/read/27799736/efficacy-and-tolerability-of-benzalkonium-chloride-free-travoprost-in-glaucoma-patients-switched-from-benzalkonium-chloride-preserved-latanoprost-or-bimatoprost
#7
Julian García-Feijoo, Francisco J Muñoz-Negrete, Douglas A Hubatsch, Gemma C Rossi
INTRODUCTION: The preservative benzalkonium chloride (BAK) is used to preserve several topical, intraocular pressure (IOP)-lowering glaucoma medications but can cause tolerability concerns that may lead to decreased adherence to treatment and ultimately diminish the effectiveness of IOP control. The study aimed to determine the efficacy and tolerability of BAK-free travoprost preserved with polyquaternium-1 in glaucoma patients switched from BAK-preserved latanoprost or bimatoprost. METHODS: This 12-week, open-label study was conducted in Europe between December 2011 and February 2013...
2016: Clinical Ophthalmology
https://www.readbyqxmd.com/read/27764023/sustained-drug-delivery-for-glaucoma-current-data-and-future-trends
#8
REVIEW
Ahmad A Aref
PURPOSE OF REVIEW: Sustained drug delivery has been recognized as a need for patients with ocular hypertension or glaucomatous optic neuropathy. Several sustained drug delivery systems and devices are currently on the horizon. This review aims to summarize initial results with these platforms, as reported in the literature, and also provide insight into their possible role in the glaucoma treatment paradigm. RECENT FINDINGS: Sustained drug delivery systems currently on the horizon include the topical bimatoprost ocular insert, travoprost and latanoprost punctal plugs, latanoprost-eluting contact lenses, bimatoprost and travoprost intraocular implants, as well as several other therapies in earlier stages of development...
March 2017: Current Opinion in Ophthalmology
https://www.readbyqxmd.com/read/27633513/tolerability-and-efficacy-of-bimatoprost-0-01%C3%A2-in-patients-with-open-angle-glaucoma-or-ocular-hypertension-evaluated-in-the-taiwanese-clinical-setting-the-asia-pacific-patterns-from-early-access-of-lumigan-0-01%C3%A2-appeal-taiwan-study
#9
MULTICENTER STUDY
Ying Ying Chen, Tsing-Hong Wang, Catherine Liu, Kwou-Yeung Wu, Shin-Lin Chiu, Susan Simonyi, Da-Wen Lu
BACKGROUND: In randomized, controlled trials of open-angle glaucoma (OAG) or ocular hypertension (OHT), bimatoprost 0.01 % improved tolerability while retaining the intraocular pressure (IOP)-lowering efficacy of bimatoprost 0.03 %. Given geographic/racial differences in glaucoma presentation, the APPEAL study assessed the occurrence and severity of hyperemia produced by bimatoprost 0.01 %, and its efficacy, in the Taiwanese clinical setting. METHODS: In this multicenter, open-label, observational study, treatment-naïve and previously treated patients with OHT or OAG received once-daily bimatoprost 0...
September 15, 2016: BMC Ophthalmology
https://www.readbyqxmd.com/read/27619225/newly-diagnosed-primary-open-angle-glaucoma-randomized-to-2-trabecular-bypass-stents-or-prostaglandin-outcomes-through-36-months
#10
Steven D Vold, Lilit Voskanyan, Manfred Tetz, Gerd Auffarth, Imran Masood, Leon Au, Iqbal Ike K Ahmed, Hady Saheb
PURPOSE: To examine outcomes through 36 months in phakic eyes with newly diagnosed primary open-angle glaucoma (POAG) naïve to therapy randomized to treatment with two trabecular micro-bypass stents or topical prostaglandin. METHODS: Subjects with POAG naïve to therapy, with intraocular pressure (IOP) ≥21 and ≤40 mmHg, were randomized to implantation of two stents or travoprost. Additional medication was to be prescribed post-treatment for elevated IOP or glaucomatous optic nerve findings...
December 2016: Ophthalmology and Therapy
https://www.readbyqxmd.com/read/27612621/prolonged-ocular-inflammation-in-endotoxin-induced-uveitis-in-lysosomal-phospholipase-a2-deficient-mice
#11
Kanako Sawada, Miki Hiraoka, Akira Abe, Robert Kelly, James A Shayman, Hiroshi Ohguro
PURPOSE: The goal of present study was to elucidate the pathophysiological roles of lysosomal phospholipase A2 (LPLA2) in intraocular pressure (IOP) levels and ocular inflammation. METHODS: C57BL/6 (wild-type) and LPLA2-deficient mice with C57BL/6 background were employed. The IOPs were compared between wild-type and LPLA2-deficient mice during their aging, after topical administration of antiglaucoma medications such as travoprost, dorzolamide, or timolol maleate, or after induction of endotoxin-induced uveitis (EIU) using lipopolysaccharide (LPS)...
September 9, 2016: Current Eye Research
https://www.readbyqxmd.com/read/27536047/evaluation-of-physical-properties-of-generic-and-branded-travoprost-formulations
#12
REVIEW
Meenakshi Wadhwani, Sanjay K Mishra, Dewang Angmo, Thirumurthy Velpandian, Ramanjit Sihota, Ankita Kotnala, Shibal Bhartiya, Tanuj Dada
PURPOSE: Comparative evaluation of pharmaceutical characteristics of three marketed generic vs branded travoprost formulations. MATERIALS AND METHODS: Three generic travoprost formulations and one branded (Travatan without benzalkonium chloride) formulation (10 vials each), obtained from authorized agents from the respective companies and having the same batch number, were used. These formulations were coded and labels were removed. At a standardized room temperature of 25°C, the drop size, pH, relative viscosity, and total drops per vial were determined for Travatan (Alcon, Fort Worth, TX, USA) and all the generic formulations...
May 2016: Journal of Current Glaucoma Practice
https://www.readbyqxmd.com/read/27506567/does-the-intraocular-pressure-lowering-effect-of-prostaglandin-analogues-continue-over-the-long-term
#13
Caner Kara, Emine Malkoç Şen, Kadriye Ufuk Elgin, Kurtuluş Serdar, Pelin Yilmazbaş
The purpose of the study is to assess the changes in the long-term effects of prostaglandin analogues (PGAs) on intraocular pressure (IOP) reduction in patients with primary open-angle glaucoma (POAG). Data of POAG patients treated with latanoprost (0.005 %), travoprost (0.004 %), or bimatoprost (0.03 %) as the first line treatment for 5 years or more were retrospectively evaluated. Baseline ophthalmic assessment values were recorded together with the IOP at the 6th month, 1st year, and then annually. The 79 patients included 33 (41...
August 9, 2016: International Ophthalmology
https://www.readbyqxmd.com/read/27456558/-quantitative-evaluation-of-uveoscleral-outflow-for-optimization-of-glaucoma-treatment
#14
G M Stolyarov, N V Tikhomirova, I V Tikhomirov
UNLABELLED: The leading role in glaucoma treatment is now played by prostaglandin analogues (PGAs), whose point of application is the uveoscleral outflow of aqueous humor. Quantitative evaluation of the latter is, however, a problem yet unsolved. AIM: To assess the clinical applicability of a new method for quantitative evaluation of the uveoscleral outflow in human eyes, which is meant to help with optimization of glaucoma therapy. MATERIAL AND METHODS: Patients with early (n=33) and advanced (n=30) primary open-angle glaucoma (POAG) were enrolled...
May 2016: Vestnik Oftalmologii
https://www.readbyqxmd.com/read/27367743/ocular-hypotensive-effect-of-fixed-combination-brinzolamide-brimonidine-adjunctive-to-a-prostaglandin-analog-a-randomized-clinical-trial
#15
R D Fechtner, J S Myers, D A Hubatsch, D L Budenz, H B DuBiner
PurposeTo determine whether intraocular pressure (IOP) lowering with fixed-combination brinzolamide/brimonidine (BBFC) adjunctive to a prostaglandin analog (PGA) was superior to that of vehicle+PGA in patients with open-angle glaucoma or ocular hypertension who were inadequately controlled with PGA monotherapyMethodsThis 6-week, multicenter, randomized, double-masked, parallel-group trial was conducted at 30 clinical sites in the United States between October 2013 and May 2014. Eligible patients were adults with open-angle glaucoma or ocular hypertension and with mean IOP ≥21 and <32 mm Hg, whereas receiving an open-label PGA (latanoprost, bimatoprost, or travoprost)...
October 2016: Eye
https://www.readbyqxmd.com/read/27330476/effects-of-topical-travoprost-0-004-on-intraocular-pressure-and-corneal-biomechanical-properties-in-an-animal-model
#16
Gabriel Lazcano-Gomez, David Ancona-Lezama, Felix Gil-Carrasco, Jesus Jimenez-Roman
PURPOSE: To determine whether topical application of travoprost 0.004% induces changes in corneal biomechanical properties affecting intraocular pressure (IOP) values in rabbits. METHODS: Both eyes of 10 New Zealand rabbits were measured 3 times with the Ocular Response Analyzer (ORA) before treatment. Each measurement included corneal hysteresis (CH), corneal resistance factor (CRF), corneal-corrected IOP (IOPcc), and Goldmann equivalent IOP (IOPg). A drop of travoprost 0...
2016: Digital Journal of Ophthalmology: DJO
https://www.readbyqxmd.com/read/27294589/effect-of-travoprost-and-nonsteroidal-anti-inflammatory-drug-on-diurnal-intraocular-pressure-in-normal-subjects-with-low-teen-baseline-intraocular-pressure
#17
Rei Sakata, Toshihiro Sakisaka, Hiroshi Matsuo, Kazunori Miyata, Makoto Aihara
PURPOSE: The main purpose was to determine whether a nonsteroidal anti-inflammatory drug (NSAID) ophthalmic solution would affect the intraocular pressure (IOP)-lowering effect of a benzalkonium chloride (BAK)-free prostaglandin analog, travoprost. The secondary purpose was to confirm the IOP-lowering effect of BAK-free travoprost on the diurnal IOP. METHODS: This was a prospective, randomized, double-blind, placebo-controlled 1-month trial. After baseline diurnal IOP was confirmed, travoprost was administered once daily to both eyes...
July 2016: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/27225879/tafluprost-ophthalmic-solution-0-0015%C3%A2-a-review-in-glaucoma-and-ocular-hypertension
#18
REVIEW
Gillian M Keating
Tafluprost ophthalmic solution 0.0015 % preserved with benzalkonium chloride (BAK) 0.001 % is available in several Asian countries, including Japan. In pivotal trials, BAK-preserved tafluprost ophthalmic solution 0.0015 % lowered intraocular pressure (IOP) more effectively than placebo in Asian patients with normal-tension glaucoma and was at least as effective as latanoprost ophthalmic solution 0.005 % in Asian patients with primary open-angle glaucoma or ocular hypertension. In other prospective studies in Asian patients with glaucoma or ocular hypertension, tafluprost ophthalmic solution 0...
June 2016: Clinical Drug Investigation
https://www.readbyqxmd.com/read/27187282/changes-in-corneal-biomechanical-properties-after-long-term-topical-prostaglandin-therapy
#19
Na Wu, Yuhong Chen, Xiaobo Yu, Mengwei Li, Wen Wen, Xinghuai Sun
OBJECTIVE: To compare corneal biomechanical properties, measured by a newly developed tonometer (Corneal Visualization Scheimpflug Technology, Corvis ST), in untreated primary open angle glaucoma (POAG) patients, POAG patients with long-term topical prostaglandin analog (PGA) therapy and in normal controls. Further is to investigate the potential effects of PGA on corneal biomechanics. METHODS: In this case-control study, 35 consecutive medication naïve eyes with POAG, 34 POAG eyes with at least 2 years treatment by PGA and 19 normal eyes were included...
2016: PloS One
https://www.readbyqxmd.com/read/27175058/feasibility-study-of-sustained-release-travoprost-punctum-plug-for-intraocular-pressure-reduction-in-an-asian-population
#20
Shamira A Perera, Daniel Sw Ting, Monisha E Nongpiur, Paul T Chew, Maria Cecilia D Aquino, Chelvin Ca Sng, Sue-Wei Ho, Tin Aung
PURPOSE: To investigate the efficacy and safety of a punctum plug-based sustained drug release system for a prostaglandin analog, travoprost (OTX-TP), for intraocular pressure (IOP) reduction in an Asian population. METHODS: This is an initial feasibility, prospective, single-arm study involving 26 eyes and a bioresorbable punctum plug containing OTX-TP. An OTX-TP was placed in the vertical portion of the superior or inferior canaliculus of patients with primary open-angle glaucoma or ocular hypertension...
2016: Clinical Ophthalmology
keyword
keyword
96072
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"